CENTEL230228R
CENTEL230228R
CENTEL230228R
4Q22 results beat our estimate and the street’s Key statistics
Market cap Bt75.3bn USD2.2bn
CENTEL reported a 4Q22 core profit of Bt382m (excluding FX gain of 12-mth price range Bt33.5/Bt56.5
Bt116m), against core profits of Bt152m for 4Q21 and Bt27m for 3Q22. 12-mth avg daily volume Bt194m USD5.6m
The result was considerably above our estimate of a Bt240m profit and # of shares (m) 1,350
Est. free float (%) 72.0
the consensus’ projection of a Bt260m profit.
Foreign limit (%) 40.0
Result highlights Share price perf. (%) 1M 3M 12M
CENTEL’s hotel revenue improved substantially by 109% YoY—the Relative to SET 10.4 13.7 65.0
Absolute 7.2 14.4 61.6
occupancy rate and average daily room rate were both much higher than
expected in 4Q22. The hotel business 4Q22 core earnings were Bt359m Financial summary
(against a loss of Bt31m for 4Q21 and a profit Bt321m for 4Q19). FY Ended 31 Dec 2022 2023E 2024E 2025E
Revenues (Btm) 17,502 22,253 24,412 28,370
QSR revenue increased 17% YoY. The growth was led by 12% SSSG Net profit (Btm) 398 1,762 2,250 2,728
and outlet expansion. The QSR business 4Q22 net profit was Bt139m EPS (Bt) 0.29 1.31 1.67 2.02
EPS growth (%) n.m. n.m. +27.7% +21.2%
(against a profit of Bt183m for 4Q21 and a profit of Bt150m for 4Q19). Core profit (Btm) 387 1,762 2,250 2,728
CENTEL’s QSR business was negatively impacted by rising food costs Core EPS (Bt) 0.29 1.31 1.67 2.02
Core EPS growth (%) n.m. n.m. +27.7% +21.2%
and SG&A expenses in 4Q22. PER (x) 146.2 42.7 33.4 27.6
PBV (x) 3.1 3.8 3.5 3.3
Outlook Dividend (Bt) 0.0 0.5 0.7 0.8
Dividend yield (%) 0.0 0.9 1.2 1.4
We expect CENTEL’s hotel business to continue to revive in 1Q23, ROE (%) 2.2 9.2 11.1 12.5
supported by Thailand-located hotels. The QSR operation should achieve
CG / CAC Anti-Corruption Certification
earnings growth, supported by a consumption recovery. Hence, we
expect YoY and QoQ profit growth for 1Q23. Yes
/
What’s changed?
Our 2023 earnings forecast remains unchanged.
Recommendation
We like CENTEL for its solid fundamentals, strong balance sheet, hotel
business turnaround story, and profitable QSR operation. BUY!
Kalvalee Thongsomaung
Securities Fundamental Investment Analyst
[email protected]
+66 2 618 1341
Please see final page for additional important disclosures. Bualuang Securities Public Company
See disclaimer at the end of report Limited (“BLS”) is a foreign broker-dealer unregistered in the USA. BLS research is prepared by
research analysts who are not registered in the USA. BLS research is distributed in the USA
pursuant to Rule 15a-6 of the Securities Exchange Act of 1934.
| RESEARCH
••• CENTEL 2
| RESEARCH
Company profile
Central Plaza Hotel Plc (CENTEL) comes under the umbrella of the Central group. It operates a range of hotels in Thailand and overseas, as well as
Quick Service Restaurants (QSRs) in Thailand. CENTEL has five key hotel brands— Centara Reserve, Centara Grand, Centara, Centra, and Cosi—
and 46 operating hotels in its portfolio as of 2021—proprietary hotels, JV hotels, and hotels under management contracts. Its food business operates 19
food brands and 1,389 outlets in Thailand. The key brands are KFC, Mister Donut, Auntie Anne’s, and Ootoya. In 2021 the food business comprised
81% (59% for 2019) of revenue and the hotel business 19% (41% for 2019).
••• CENTEL 3
| RESEARCH
FY Ended 31 Dec (Btm) 4Q22 4Q21 YoY % 3Q22 QoQ % 2022 2021 YoY %
Income Statement
Revenue 5,195 3,653 42 4,433 17 17,502 11,211 56
Cost of sales and services (3,021) (2,194) 38 (2,669) 13 (10,494) (7,613) 38
EBITDA 1,281 908 41 952 nm 3,846 1,690 128 The hotel biz marked a net profit
EBIT 516 214 nm 159 nm 713 (1,477) nm of Bt359m for 4Q22 (a loss of
Interest expense (193) (167) 15 (184) nm (726) (718) 1
Other income/exp. 111 95 17 139 (20) 598 424 41
Bt31m for 4Q21 and a profit pf
Equity earnings from affiliates 23 (25) nm (48) nm (44) (64) nm Bt321m for 4Q19)
Extra items 116 0 nm (105) nm 11 0 nm
EBT 435 142 nm 114 282 585 (1,771) nm
Corporate tax (65) 74 nm (51) 28 (138) 78 nm
The QSR biz reported a net profit
Minority interest (11) (38) nm 12 nm (16) 24 nm of Bt139m for 4Q22 (a profit of
Net profit (loss) 498 152 nm (78) nm 398 (1,733) nm Bt184m for 4Q21 and a profit of
Reported EPS 0.37 0.11 nm (0.06) nm 0.29 (1.28) nm Bt50m for 4Q19)
Core net profit 382 152 nm 27 1,317 387 (1,733) nm
Balance Sheet
Cash & Equivalent 3,137 3,354 (6) 3,359 (7)
Total assets 48,166 48,593 (1) 48,487 (1)
ST debts & current portion 5,991 5,040 19 6,013 (0)
Long-term debt 9,293 10,578 (12) 9,604 (3)
Total liabilities 29,275 30,161 (3) 29,656 (1)
Retained earnings 6,206 5,808 7 5,708 9
Shareholders equity 18,518 18,076 2 18,451 0
Minority interests 373 355 5 380 (2)
BV (Bt) 14.0 13.7 2 13.9 0
••• CENTEL 4
| RESEARCH
CENTEL is committed to enhancing the CENTEL was listed in the Thailand Sus-
potential and quality of life of employees, tainability Index (THSI) in 2021. It was also the
supporting equality and human rights, and recipient of an “Excellent” CG scoring from the
helping society. In 2021, it achieved 88.9% of Thai Institute of Directors Association in 2021.
its goal to have female managers in its hotel CENTEL joined the Thai Private Sector
and food businesses comprising more than Collective Action Coalition Against Corruption
50% of the total. CENTEL focuses on hiring (CAC) since 2016.
local people, and providing income-generating All managers and executives are required to
opportunities to vulnerable, such as people with review the company’s Code of Conduct and
disabilities, the underprivileged, and the elderly, take a test—90.37% of employees at
and supporting local products and services to supervisory and operational levels took the test
generate economic growth for nearby during 2021. CENTEL has achieved 37%
communities. progress in encouraging suppliers to sign Code
. of Conduct & Guidelines for business partners
and suppliers.
••• CENTEL 5
| RESEARCH
BUALUANG SECURITIES PUBLIC COMPANY LIMITED (BLS) is a subsidiary of BANGKOK BANK PUBLIC COMPANY LIMITED (BBL). This document
is produced based upon sources believed to be reliable but their accuracy, completeness or correctness is not guaranteed. The statements or
expressions of opinion herein were arrived at after due and careful consideration to use as information for investment. Expressions of opinion contained
herein are subject to change without notice. This document is not, and should not be construed as, an offer or the solicitation of an offer to buy or sell
any securities. The use of any information shall be at the sole discretion and risk of the user.
BUALUANG SECURITIES PUBLIC COMPANY LIMITED MAY BE IN RELATIONSHIP WITH THE SECURITIES IN THIS REPORT. “Opinions,
projections and other information contained in this report are based upon sources believed to be accurate including the draft prospectus, but no
responsibility is accepted for any loss occasioned by reliance placed upon the contents hereof. Bualuang Securities Public Company Limited may from
time to time perform investment, advisory or other services for companies mentioned in this report, as well as dealing (as principal or otherwise) in, or
otherwise being interested in, any securities mentioned herein, This report does not constitute a solicitation to buy or sell any securities”. Investors
should carefully read details in the prospectus before making investment decision.
BUALUANG SECURITIES PUBLIC COMPANY LIMITED MAY ACT AS MARKET MAKER AND ISSUER OF DWs, AND ISSUER OF STRUCTURED
NOTES ON THESE SECURITIES. The company may prepare the research reports on those underlying securities. Investors should carefully read the
details of the derivative warrants and structured notes in the prospectus before making investment decisions.
ADVANC AEONTS AMATA AOT BDMS BH CBG CENTEL CPALL DTAC EGCO GLOBAL GPSC IRPC KBANK
KCE KTC MINT PTG PTT PTTEP PTTGC SCB SPRC TASCO TOP WHA ESSO CKP STA
BGRIM GULF MTC AWC TCAP CRC CPF CPN HANA HMPRO IVL OSP SAWAD THANI BANPU
BCH BTS CK SCC STEC TISCO TRUE TU INTUCH RATCH VGI SCGP TQM COM7 DOHOME
JMT CHG TMB BAM BCP BCPG AP KTB KKP OR BEM GUNKUL LH EA SPALI
RBF EPG STGT MAJOR MEGA ACE JMART BEC SYNEX QH BLA KEX RCL SINGER SIRI
STARK TIDLOR TTA RS FORTH PSL TIPH
Lead underwriter/
Financial Advisor Underwriter/
Co-underwriter
CG Rating
Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC)
under Thai Institute of Directors
companies that have declared their intention to join CAC, and
companies certified by CAC.
••• CENTEL 6
| RESEARCH
This research report was prepared by Bualuang Securities Public Company Limited and refers to research prepared by Morgan Stanley. Morgan Stanley
does not warrant or guarantee the accuracy or completeness of its research reports. Morgan Stanley reserves copyright and other proprietary rights in
the material reproduced in this report. Morgan Stanley is under no obligation to inform Bualuang Securities or you if the views or information referred to
or reproduced in this research report change.
“Disclaimer: The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by the
relevant institution as disclosed by the Office of the Securities and Exchange Commission, is made in order to comply with the policy and sustainable
development plan for the listed companies. The relevant institution made this assessment based on the information received from the listed company, as
stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2),
or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of a third party. It is not an
assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the
assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, Bualuang Securities Public
Company Limited neither confirms, verifies, nor certifies the accuracy and completeness of the assessment result.”
BUY: Expected positive total returns of 15% or more over the next 12 OVERWEIGHT: The industry, as defined by the analyst's coverage universe, is
months. expected to outperform the relevant primary market index over the next 12 months.
HOLD: Expected total returns of between -15% and +15% over the next 12 NEUTRAL: The industry, as defined by the analyst's coverage universe, is
months. expected to perform in line with the relevant primary market index over the next 12
SELL: Expected negative total returns of 15% or more over the next 12 months.
months. UNDERWEIGHT: The industry, as defined by the analyst's coverage universe, is
TRADING BUY: Expected positive total returns of 15% or more over the next expected to underperform the relevant primary market index over the next 12
3 months. months.
••• CENTEL 7
| RESEARCH
This research report was prepared by Bualuang Securities Public Company Limited (“BLS”). BLS is not a registered broker-dealer in the
United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research
analysts. This research report is provided for distribution to “major U.S. institutional investors” in reliance on the exemption from
registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial
instruments through BLS. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set
out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.
The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry
Regulatory Authority (“FINRA”) and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to
applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by
a research analyst account.
Additional Disclosures
This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no
regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single
recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or
developments referred to in this research report. Neither BLS nor any of its directors, officers, employees or agents shall have any liability,
however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research
report’s preparation or publication, or any losses or damages which may arise from the use of this research report.
BLS may rely on information barriers, such as “Chinese Walls” to control the flow of information within the areas, units, divisions, groups,
or affiliates of BLS.
Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain
risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange
Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be
subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.
The value of any investment or income from any securities or related financial instruments discussed in this research report denominated
in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or
income from such securities or related financial instruments.
Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by BLS
with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research
report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this
research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under
analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.
No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior
consent of BLS and BLS accepts no liability whatsoever for the actions of third parties in this respect.
••• CENTEL 8